Zacks Research Issues Negative Estimate for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX) – Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Becton, Dickinson and Company in a research report issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $3.28 per share for the quarter, down from their previous forecast of $3.45. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2025 earnings at $3.58 EPS, Q4 2025 earnings at $4.14 EPS, Q1 2026 earnings at $3.21 EPS, Q2 2026 earnings at $3.79 EPS, Q3 2026 earnings at $4.06 EPS and Q1 2027 earnings at $3.46 EPS.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%.

Several other research firms have also commented on BDX. Piper Sandler increased their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Barclays increased their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Trading Down 1.4 %

Shares of NYSE:BDX opened at $224.44 on Friday. The company has a market cap of $64.44 billion, a PE ratio of 37.28, a P/E/G ratio of 1.63 and a beta of 0.40. The company’s 50 day moving average is $233.13 and its two-hundred day moving average is $233.11. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. E. Ohman J or Asset Management AB boosted its position in shares of Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after buying an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $767,000. Busey Bank increased its holdings in Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after acquiring an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,544 shares of company stock worth $2,370,309. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.